About Nuvalent
Nuvalent (NASDAQ:NUVL) specializes in creating precisely targeted therapies for patients with cancer. Dedicated to advancing the treatment of cancer, their operations focus on developing a robust portfolio of innovative drugs designed to address the limitations of existing therapies. Their projects aim to tackle molecularly defined cancers by discovering and developing chemically advanced, selective small molecules that are intended to overcome drug resistance and improve patient outcomes. The objective at Nuvalent is to push the boundaries of cancer treatment, ensuring more effective and safer therapeutic options are available to those in need. Through meticulous research and development efforts, Nuvalent is committed to fulfilling unmet medical needs in the oncology space.
Snapshot
Operations
Products and/or services of Nuvalent
- Development of novel kinase inhibitors with improved therapeutic profiles for cancer treatment.
- Advancement of ROS1-selective inhibitors, aiming at non-small cell lung cancer therapy.
- Progression of ALK-selective inhibitors to treat ALK-driven cancers.
- Research in overcoming treatment resistance in cancer therapy through precision medicine.
- Provision of a proprietary discovery platform for targeted therapies.
- Collaboration with academic institutions and industry partners to accelerate drug development.
Nuvalent executive team
- Dr. James R. Porter Ph.D.CEO, President & Director
- Ms. Alexandra Balcom CPA, M.B.A.CFO & Treasurer
- Ms. Deborah Ann Miller J.D., Ph.D.Chief Legal Officer & Secretary
- Ms. Darlene NociChief Development Officer
- Dr. Christopher D. Turner M.D.Chief Medical Officer
- Dr. Benjamin Lane Ph.D.Senior Vice President of Technical Operations
- Dr. Henry Pelish Ph.D.Chief Scientific Officer
- Chelcie ListerSenior Director of Investor Relations & Corporate Communications
- Mr. Matthew Metivier M.B.A.Senior Vice President of Human Resources
- Mr. John Soglia Ph.D.Senior Vice President of Translational Development